Sign up to save your podcasts
Or
Share The Lens Newsletter: February 12, 2025
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Lens Newsletter: February 12, 2025
Too busy to read the Lens? Listen to our weekly summary here! In this week’s episode we discuss…
- Brolucizumab provided non-inferior outcomes compared to aflibercept in nAMD eyes with persistent retinal fluid, but was associated with more adverse ocular events.
A case series study evaluated the ophthalmic complications associated with semaglutide and tirzepatide used for treatment of diabetes.
The distinct ocular surface microbiome found in keratoconus patients may correlate with local immune dysregulation that contributes to disease pathogenesis.
View all episodes
By Lens Pod
5
55 ratings
Too busy to read the Lens? Listen to our weekly summary here! In this week’s episode we discuss…
- Brolucizumab provided non-inferior outcomes compared to aflibercept in nAMD eyes with persistent retinal fluid, but was associated with more adverse ocular events.
A case series study evaluated the ophthalmic complications associated with semaglutide and tirzepatide used for treatment of diabetes.
The distinct ocular surface microbiome found in keratoconus patients may correlate with local immune dysregulation that contributes to disease pathogenesis.